NatureWise Biotech & Medicals Corporation (TPEX:4732)
Taiwan · Delayed Price · Currency is TWD 19.00
-0.05 (-0.26%)
May 29, 2026, 1:11 PM CST
TPEX:4732 Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 176.77 | 224.32 | 160.14 | 228.59 | 249.8 | |
Revenue Growth (YoY) | -21.20% | 40.08% | -29.94% | -8.49% | -18.61% |
Cost of Revenue | 91.07 | 104.12 | 72.76 | 98.66 | 103.62 |
Gross Profit | 85.7 | 120.2 | 87.38 | 129.93 | 146.19 |
Selling, General & Admin | 54.15 | 60.17 | 53.94 | 54.06 | 49.75 |
Research & Development | 138.41 | 72.07 | 30.01 | 49.48 | 69.46 |
Operating Expenses | 192.57 | 132.22 | 83.95 | 103.58 | 119.21 |
Operating Income | -106.87 | -12.02 | 3.43 | 26.35 | 26.98 |
Interest Expense | -0.07 | -0.1 | -0.05 | -0.04 | -0.03 |
Interest & Investment Income | 7.59 | 6.64 | 5.96 | 3.61 | 1.98 |
Currency Exchange Gain (Loss) | - | 1.72 | 0.05 | -0.05 | 0.54 |
Other Non Operating Income (Expenses) | -2.19 | 0.1 | 0.1 | -0.16 | 1.25 |
EBT Excluding Unusual Items | -101.54 | -3.65 | 9.49 | 29.71 | 30.72 |
Gain (Loss) on Sale of Investments | - | - | 0.44 | 0.31 | -0.08 |
Gain (Loss) on Sale of Assets | - | - | - | 0 | - |
Pretax Income | -101.54 | -3.65 | 9.92 | 30.02 | 30.64 |
Income Tax Expense | 16.9 | -0.07 | -0.2 | - | -0.17 |
Earnings From Continuing Operations | -118.43 | -3.58 | 10.12 | 30.02 | 30.81 |
Minority Interest in Earnings | 26.15 | 4.48 | - | - | - |
Net Income | -92.28 | 0.9 | 10.12 | 30.02 | 30.81 |
Net Income to Common | -92.28 | 0.9 | 10.12 | 30.02 | 30.81 |
Net Income Growth | - | -91.14% | -66.29% | -2.54% | -52.83% |
Shares Outstanding (Basic) | 49 | 49 | 49 | 49 | 49 |
Shares Outstanding (Diluted) | 49 | 50 | 50 | 49 | 49 |
Shares Change (YoY) | -2.02% | -0.15% | 0.85% | 0.30% | -0.05% |
EPS (Basic) | -1.89 | 0.02 | 0.21 | 0.61 | 0.63 |
EPS (Diluted) | -1.89 | 0.02 | 0.20 | 0.61 | 0.62 |
EPS Growth | - | -90.90% | -67.17% | -1.75% | -53.03% |
Free Cash Flow | -112.58 | -2.91 | 61.9 | 13.85 | 33.72 |
Free Cash Flow Per Share | -2.31 | -0.06 | 1.24 | 0.28 | 0.68 |
Dividend Per Share | - | - | 0.200 | 0.500 | 0.300 |
Dividend Growth | - | - | -60.00% | 66.67% | 218.13% |
Gross Margin | 48.48% | 53.58% | 54.56% | 56.84% | 58.52% |
Operating Margin | -60.46% | -5.36% | 2.14% | 11.53% | 10.80% |
Profit Margin | -52.20% | 0.40% | 6.32% | 13.13% | 12.33% |
Free Cash Flow Margin | -63.69% | -1.30% | 38.65% | 6.06% | 13.50% |
EBITDA | -95.81 | -5.57 | 9.84 | 37.15 | 38.01 |
EBITDA Margin | -54.20% | -2.48% | 6.14% | 16.25% | 15.22% |
D&A For EBITDA | 11.06 | 6.45 | 6.4 | 10.8 | 11.03 |
EBIT | -106.87 | -12.02 | 3.43 | 26.35 | 26.98 |
EBIT Margin | -60.46% | -5.36% | 2.14% | 11.53% | 10.80% |